

Analysis of Deals in Neurodegenerative Diseases

Dr Danya Morton-Holmes and Nick Fyson
with members of PharmaVentures Corporate Advisory

Copyright © 2010 PharmaVentures Ltd

Published by PharmaDeals, Imprint of PharmaVentures Ltd
Florey House, Oxford Science Park, Oxford, OX4 4GP, UK
www.pharmaventures.com

Copyright © 2010 PharmaVentures Ltd

PharmaDeals® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

Published by PharmaDeals, Imprint of PharmaVentures Ltd
Florey House, Oxford Science Park, Oxford, OX4 4GP, UK
www.pharmaventures.com

Published July 2010

British Library Cataloguing in Publication Data
Morton-Holmes, Danya.

ISBN:

All copyright and intellectual property rights in this report and its contents belong to PharmaVentures Ltd. Distribution and commercialisation rights are solely vested in PharmaVentures Ltd.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the express permission in writing of PharmaVentures Ltd. Enquiries concerning the sale and reproduction of this title, including translation rights, should be sent to PharmaDeals, at the address given above.

Disclaimer: PharmaVentures Ltd does not accept any responsibility or liability for any damage or loss arising from the direct or indirect use of this work, and all warranties, expressed or implied are disclaimed.

This report has been prepared based on information taken from a variety of sources including public domain sources deemed to be reliable by PharmaVentures Ltd, PharmaVentures' proprietary databases and is complemented by the experience and judgement of PharmaVentures' Corporate Advisory team. While every effort has been made to ensure the accuracy and completeness of this report, PharmaVentures cannot accept liability for errors or omissions. Material contained in this report is for general information only and is not intended to be relied upon by individuals or companies in making (or refraining from making) any specific investment or alliance decisions. For detailed information contact PharmaDeals at the address given above.

<http://www.pharmadeals.net>

Contents

1		3.2	Trends in deal making in Parkinson's disease.....	35
	Introduction to neurodegenerative diseases	3.2.1	Analysis of deals by deal type	36
1.1	Overview.....	3.2.2	Deals by stage of development.....	38
1.2	Overall trends in neurodegenerative disease deals	3.2.3	Deals by product type.....	40
1.2.1	Comparison with other therapy areas... ..	3.2.4	Key players.....	41
1.2.2	Number of deals.....	4		
1.2.3	Value of deals.....		Multiple sclerosis	44
1.3	Key players.....	4.1	Overview.....	44
1.4	Deals by territory.....	4.1.1	Epidemiology	45
1.5	Impact of the 'credit crunch'	4.1.2	Market size and trends	45
1.6	Royalties.....	4.1.3	Current therapies	46
2		4.1.4	Future treatments – products in development	47
	Alzheimer's disease	4.2	Trends in deal making in Multiple sclerosis.....	48
2.1	Overview.....	4.2.1	Analysis of deals by deal type	49
2.1.1	Epidemiology	4.2.2	Deals by stage of development.....	51
2.1.2	Market size	4.2.3	Deals by product type.....	52
2.1.3	Current therapies	4.2.4	Key players.....	53
2.1.4	Future treatments – products in development	5		
2.2	Trends in deal making in Alzheimer's disease ...		Epilepsy	55
2.2.1	Overview.....	5.1	Overview.....	55
2.2.2	Analysis of deals by deal type	5.1.1	Epidemiology	56
2.2.3	Deals by stage of development.....	5.1.2	Market size and trends	56
2.2.4	Deals by product type.....	5.1.3	Current therapies	57
2.2.5	Key players.....	5.1.4	Future treatments – products in development	58
3		5.2	Trends in deal making in Epilepsy.....	58
	Parkinson's Disease	5.2.1	Analysis of deals by deal type	60
3.1	Overview.....	5.2.2	Deals by stage of development.....	61
3.1.1	Epidemiology	5.2.3	Key players.....	62
3.1.2	Market size and trends			
3.1.3	Current therapies			
3.1.4	Future treatments – products in development			

6		8	
Migraine	63	Appendix 1: Alzheimer's disease deals	75
6.1 Overview	63	8.1 J&J and Elan	75
6.1.1 Epidemiology	64	8.2 TorreyPines and Eisai	77
6.1.2 Market size and trends	64	8.3 Medivation and Pfizer	79
6.1.3 Current therapies	64	8.4 Myriad Genetics and Lundbeck	81
6.1.4 Future treatments – products in development	66	8.5 CoMentis and Astellas	83
6.2 Trends in deal making in Migraine	67	8.6 Ablynx and Boehringer	85
6.2.1 Analysis of deals by deal type	68	9	
6.2.2 Deals by stage of development	69	Appendix 2: Parkinson's Disease deals	87
6.2.3 Key players	70	9.1 Newron Pharmaceuticals and Serono	87
7		9.2 Biovail and Acadia	89
Conclusions	72	10	
		Appendix 3: Multiple sclerosis deals	91
		10.1 Facet Biotech and Abbott	91
		10.2 Bayer Schering and Genzyme	93
		10.3 BioMS Medical Corp and Eli Lilly	95
		10.4 Acorda Therapeutics and Biogen Idec	97
		10.5 Fast Forward LLC and Merck Serono	99
		11	
		Appendix 4: Epilepsy deals	101
		11.1 Valeant and GSK	101
		11.2 BIAL Group and Sepracor	103
		12	
		Appendix 4: Migraine deals	105
		12.1 Pozen and GSK	105

Tables

1	Prevalence rates for dementia by age group	18
2	Main drugs currently marketed for AD	19
3	Products in Phase III development for AD.....	20
4	Selected AD deals.....	21
5	AD drugs providing symptomatic relief	26
6	Potentially disease-modifying AD agents.....	26
7	Diagnostics.....	27
8	Top AD dealmakers (1996 to 2009)	27
9	Pfizer/Wyeth late stage AD pipeline	28
10	Top AD principal/originator organisations (1996 to 2009).....	28
11	Elan's involvement in later stage AD drugs.....	29
12	Products in Phase III development for PD	34
13	Top PD dealmakers (1996 to 2009).....	41
14	Top PD principal/originator organisations (1996 to 2009).....	43
15	Products in late stage development for MS.....	48
16	Top MS dealmakers (1996 to 2009).....	53
17	Top MS principal/originator organisations (1996 to 2009).....	53
18	Biogen Idec's MS pipeline portfolio	54
19	Products in later stage development for epilepsy	58
20	Top epilepsy dealmakers (1996 to 2009).....	62
21	Top epilepsy principal/originator organisations (1996 to 2009).....	62
22	Products in later stage development for migraine	66
23	Top migraine dealmakers (1996 to 2009).....	70

Figures

1	Deal intensity by therapeutic area (1996 to 2009).....	9	15	Deal type by value.....	38
2	Number of deals in five neurodegenerative disease areas (1996 to 2009).....	9	16	Number of PD deals by stage of development.....	39
3	Value of deals in five neurodegenerative disease areas (1996 to 2009).....	11	17	Average value of PD deals by stage of development.....	40
4	Number of deals by territory in five neurodegenerative disease areas (1996 to 2009).....	13	18	2009 worldwide sales of MS drugs (US\$M)	46
5	Impact of the credit crunch on deal-making	14	19	Total MS deals by deal type	50
6	Disclosed royalty rates for selected neurodegenerative diseases deals	15	20	Year on year analysis by deal type.....	50
7	2009 worldwide sales of AD drugs (US\$ M).....	18	21	Deal type by value.....	50
8	Total AD deals by deal type.....	22	22	Number of MS deals by stage of development.....	51
9	Year on year analysis by deal type.....	22	23	Average value of MS deals by stage of development.....	52
10	Deal type by value.....	23	24	Total epilepsy deals by deal type	60
11	Number of AD deals by stage of development.....	24	25	Deal type by value.....	61
12	Average value of AD deals by stage of development.....	25	26	Number of epilepsy deals by stage of development.....	61
13	Total PD deals by deal type	37	27	Total migraine deals by deal type	68
14	Year on year analysis by deal type.....	37	28	Number of migraine deals by stage of development.....	69
			29	Average value of migraine deals by stage of development.....	69